ID   RSPO2_HUMAN             Reviewed;         243 AA.
AC   Q6UXX9; B3KVP0; Q4G0U4; Q8N6X6;
DT   16-MAY-2006, integrated into UniProtKB/Swiss-Prot.
DT   15-MAY-2007, sequence version 2.
DT   07-APR-2021, entry version 140.
DE   RecName: Full=R-spondin-2;
DE   AltName: Full=Roof plate-specific spondin-2;
DE            Short=hRspo2;
DE   Flags: Precursor;
GN   Name=RSPO2; ORFNames=UNQ9384/PRO34209;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT PRO-186.
RX   PubMed=12975309; DOI=10.1101/gr.1293003;
RA   Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
RA   Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA   Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S., Huang A.,
RA   Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J., Lewis L., Liao D.,
RA   Mark M.R., Robbie E., Sanchez C., Schoenfeld J., Seshagiri S., Simmons L.,
RA   Singh J., Smith V., Stinson J., Vagts A., Vandlen R.L., Watanabe C.,
RA   Wieand D., Woods K., Xie M.-H., Yansura D.G., Yi S., Yu G., Yuan J.,
RA   Zhang M., Zhang Z., Goddard A.D., Wood W.I., Godowski P.J., Gray A.M.;
RT   "The secreted protein discovery initiative (SPDI), a large-scale effort to
RT   identify novel human secreted and transmembrane proteins: a bioinformatics
RT   assessment.";
RL   Genome Res. 13:2265-2270(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT PRO-186.
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M.,
RA   Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L.,
RA   Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S.,
RA   Asakawa T., Blechschmidt K., Bloom T., Borowsky M.L., Butler J., Cook A.,
RA   Corum B., DeArellano K., DeCaprio D., Dooley K.T., Dorris L. III,
RA   Engels R., Gloeckner G., Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K.,
RA   Jaffe D.B., Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C., O'Leary S.B.,
RA   O'Neill K., Parker S.C.J., Polley A., Raymond C.K., Reichwald K.,
RA   Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R., Smith C.L.,
RA   Sneddon T.P., Talamas J.A., Tenzin P., Topham K., Venkataraman V., Wen G.,
RA   Yamazaki S., Young S.K., Zeng Q., Zimmer A.R., Rosenthal A., Birren B.W.,
RA   Platzer M., Shimizu N., Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT PRO-186.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3), AND VARIANT
RP   PRO-186.
RC   TISSUE=Lung, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   FUNCTION, AND INTERACTION WITH LGR4 AND LGR5.
RX   PubMed=21909076; DOI=10.1038/embor.2011.175;
RA   Glinka A., Dolde C., Kirsch N., Huang Y.L., Kazanskaya O., Ingelfinger D.,
RA   Boutros M., Cruciat C.M., Niehrs C.;
RT   "LGR4 and LGR5 are R-spondin receptors mediating Wnt/beta-catenin and
RT   Wnt/PCP signalling.";
RL   EMBO Rep. 12:1055-1061(2011).
RN   [7]
RP   FUNCTION, AND INTERACTION WITH LGR4; LGR5 AND LGR6.
RX   PubMed=21727895; DOI=10.1038/nature10337;
RA   de Lau W., Barker N., Low T.Y., Koo B.K., Li V.S., Teunissen H., Kujala P.,
RA   Haegebarth A., Peters P.J., van de Wetering M., Stange D.E., van Es J.E.,
RA   Guardavaccaro D., Schasfoort R.B., Mohri Y., Nishimori K., Mohammed S.,
RA   Heck A.J., Clevers H.;
RT   "Lgr5 homologues associate with Wnt receptors and mediate R-spondin
RT   signalling.";
RL   Nature 476:293-297(2011).
RN   [8]
RP   FUNCTION, AND INTERACTION WITH LGR6.
RX   PubMed=22615920; DOI=10.1371/journal.pone.0037137;
RA   Gong X., Carmon K.S., Lin Q., Thomas A., Yi J., Liu Q.;
RT   "LGR6 is a high affinity receptor of R-spondins and potentially functions
RT   as a tumor suppressor.";
RL   PLoS ONE 7:E37137-E37137(2012).
RN   [9]
RP   INVOLVEMENT IN TETAMS2, VARIANTS TETAMS2 70-GLN--GLN-243 DEL AND
RP   137-GLU--GLN-243 DEL, INVOLVEMENT IN HHRRD, VARIANT HHRRD CYS-69,
RP   CHARACTERIZATION OF VARIANT TETAMS2 70-GLN--GLN-243, CHARACTERIZATION OF
RP   VARIANT HHRRD CYS-69, FUNCTION, INTERACTION WITH LGR5; RNF43 AND ZNRF3, AND
RP   MUTAGENESIS OF PHE-105 AND PHE-109.
RX   PubMed=29769720; DOI=10.1038/s41586-018-0118-y;
RA   Szenker-Ravi E., Altunoglu U., Leushacke M., Bosso-Lefevre C., Khatoo M.,
RA   Thi Tran H., Naert T., Noelanders R., Hajamohideen A., Beneteau C.,
RA   de Sousa S.B., Karaman B., Latypova X., Basaran S., Yuecel E.B., Tan T.T.,
RA   Vlaminck L., Nayak S.S., Shukla A., Girisha K.M., Le Caignec C.,
RA   Soshnikova N., Uyguner Z.O., Vleminckx K., Barker N., Kayserili H.,
RA   Reversade B.;
RT   "RSPO2 inhibition of RNF43 and ZNRF3 governs limb development independently
RT   of LGR4/5/6.";
RL   Nature 557:564-569(2018).
CC   -!- FUNCTION: Activator of the canonical Wnt signaling pathway by acting as
CC       a ligand for LGR4-6 receptors. Upon binding to LGR4-6 (LGR4, LGR5 or
CC       LGR6), LGR4-6 associate with phosphorylated LRP6 and frizzled receptors
CC       that are activated by extracellular Wnt receptors, triggering the
CC       canonical Wnt signaling pathway to increase expression of target genes.
CC       Also regulates the canonical Wnt/beta-catenin-dependent pathway and
CC       non-canonical Wnt signaling by acting as an inhibitor of ZNRF3, an
CC       important regulator of the Wnt signaling pathway (PubMed:21909076,
CC       PubMed:21727895, PubMed:22615920). During embryonic development, plays
CC       a crucial role in limb specification, amplifying the Wnt signaling
CC       pathway independently of LGR4-6 receptors, possibly by acting as a
CC       direct antagonistic ligand to RNF43 and ZNRF3, hence governing the
CC       number of limbs an embryo should form (PubMed:29769720).
CC       {ECO:0000269|PubMed:21727895, ECO:0000269|PubMed:21909076,
CC       ECO:0000269|PubMed:22615920, ECO:0000269|PubMed:29769720}.
CC   -!- SUBUNIT: Interacts with WNT1 (By similarity). Binds heparin (By
CC       similarity). Interacts with LGR4, LGR5 and LGR6 (PubMed:21909076,
CC       PubMed:21727895, PubMed:22615920, PubMed:29769720). Interacts with E3
CC       ubiquitin ligases RNF43 and ZNRF3 (PubMed:29769720).
CC       {ECO:0000250|UniProtKB:Q8BFU0, ECO:0000269|PubMed:21727895,
CC       ECO:0000269|PubMed:21909076, ECO:0000269|PubMed:22615920,
CC       ECO:0000269|PubMed:29769720}.
CC   -!- INTERACTION:
CC       Q6UXX9; P60372: KRTAP10-4; NbExp=3; IntAct=EBI-8481036, EBI-10178153;
CC       Q6UXX9; P60409: KRTAP10-7; NbExp=3; IntAct=EBI-8481036, EBI-10172290;
CC       Q6UXX9; P60411: KRTAP10-9; NbExp=3; IntAct=EBI-8481036, EBI-10172052;
CC       Q6UXX9; Q9H8W4: PLEKHF2; NbExp=3; IntAct=EBI-8481036, EBI-742388;
CC       Q6UXX9-2; Q8NEC5: CATSPER1; NbExp=3; IntAct=EBI-12009390, EBI-744545;
CC       Q6UXX9-2; A8MQ03: CYSRT1; NbExp=3; IntAct=EBI-12009390, EBI-3867333;
CC       Q6UXX9-2; P49639: HOXA1; NbExp=3; IntAct=EBI-12009390, EBI-740785;
CC       Q6UXX9-2; P60371: KRTAP10-6; NbExp=3; IntAct=EBI-12009390, EBI-12012928;
CC       Q6UXX9-2; P60409: KRTAP10-7; NbExp=3; IntAct=EBI-12009390, EBI-10172290;
CC       Q6UXX9-2; P60328: KRTAP12-3; NbExp=3; IntAct=EBI-12009390, EBI-11953334;
CC       Q6UXX9-2; Q92504: SLC39A7; NbExp=3; IntAct=EBI-12009390, EBI-1051105;
CC       Q6UXX9-2; Q7Z699: SPRED1; NbExp=3; IntAct=EBI-12009390, EBI-5235340;
CC       Q6UXX9-2; Q9Y3S2: ZNF330; NbExp=3; IntAct=EBI-12009390, EBI-373456;
CC       Q6UXX9-2; Q96EG3: ZNF837; NbExp=3; IntAct=EBI-12009390, EBI-11962574;
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000250|UniProtKB:Q8BFU0}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q6UXX9-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q6UXX9-2; Sequence=VSP_018321;
CC       Name=3;
CC         IsoId=Q6UXX9-3; Sequence=VSP_018322, VSP_018323;
CC   -!- DOMAIN: The FU repeat is required for activation and stabilization of
CC       beta-catenin. {ECO:0000250}.
CC   -!- DISEASE: Tetraamelia syndrome 2 (TETAMS2) [MIM:618021]: A form of
CC       tetraamelia, a rare disease characterized by rudimentary appendages or
CC       complete absence of all four limbs, and other anomalies such as
CC       craniofacial, nervous system, pulmonary, skeletal and urogenital
CC       defects. TETAMS2 patients manifest limb deformities, bilateral agenesis
CC       of the lungs, abnormalities of the pulmonary vasculature, labioscrotal
CC       fold aplasia, and dysmorphic features including bilateral cleft
CC       lip/palate, ankyloglossia, mandibular hypoplasia, and
CC       microretrognathia. TETAMS2 transmission pattern is consistent with
CC       autosomal recessive inheritance. {ECO:0000269|PubMed:29769720}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- DISEASE: Humerofemoral hypoplasia with radiotibial ray deficiency
CC       (HHRRD) [MIM:618022]: A severe disease characterized by reduction of
CC       all four limbs as well as hypoplasia of the upper limb girdle and
CC       pelvis. Rudimentary finger- or toe-like appendages may be present.
CC       HHRRD transmission pattern is consistent with autosomal recessive
CC       inheritance. {ECO:0000269|PubMed:29769720}. Note=The disease is caused
CC       by variants affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the R-spondin family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY358166; AAQ88533.1; -; mRNA.
DR   EMBL; AK123023; BAG53852.1; -; mRNA.
DR   EMBL; AC025508; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP003479; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471060; EAW91916.1; -; Genomic_DNA.
DR   EMBL; BC027938; AAH27938.1; -; mRNA.
DR   EMBL; BC036554; AAH36554.1; -; mRNA.
DR   CCDS; CCDS6307.1; -. [Q6UXX9-1]
DR   CCDS; CCDS64953.1; -. [Q6UXX9-3]
DR   CCDS; CCDS83314.1; -. [Q6UXX9-2]
DR   RefSeq; NP_001269792.1; NM_001282863.1. [Q6UXX9-3]
DR   RefSeq; NP_001304871.1; NM_001317942.1. [Q6UXX9-2]
DR   RefSeq; NP_848660.3; NM_178565.4. [Q6UXX9-1]
DR   SMR; Q6UXX9; -.
DR   BioGRID; 131049; 21.
DR   IntAct; Q6UXX9; 16.
DR   MINT; Q6UXX9; -.
DR   STRING; 9606.ENSP00000276659; -.
DR   GlyGen; Q6UXX9; 1 site.
DR   PhosphoSitePlus; Q6UXX9; -.
DR   BioMuta; RSPO2; -.
DR   DMDM; 147744588; -.
DR   PaxDb; Q6UXX9; -.
DR   PeptideAtlas; Q6UXX9; -.
DR   PRIDE; Q6UXX9; -.
DR   ProteomicsDB; 67672; -. [Q6UXX9-1]
DR   ProteomicsDB; 67673; -. [Q6UXX9-2]
DR   ProteomicsDB; 67674; -. [Q6UXX9-3]
DR   Antibodypedia; 26506; 134 antibodies.
DR   Ensembl; ENST00000276659; ENSP00000276659; ENSG00000147655. [Q6UXX9-1]
DR   Ensembl; ENST00000517781; ENSP00000427937; ENSG00000147655. [Q6UXX9-3]
DR   Ensembl; ENST00000517939; ENSP00000428940; ENSG00000147655. [Q6UXX9-2]
DR   GeneID; 340419; -.
DR   KEGG; hsa:340419; -.
DR   UCSC; uc003ymq.4; human. [Q6UXX9-1]
DR   CTD; 340419; -.
DR   DisGeNET; 340419; -.
DR   GeneCards; RSPO2; -.
DR   HGNC; HGNC:28583; RSPO2.
DR   HPA; ENSG00000147655; Tissue enhanced (brain, placenta).
DR   MalaCards; RSPO2; -.
DR   MIM; 610575; gene.
DR   MIM; 618021; phenotype.
DR   MIM; 618022; phenotype.
DR   neXtProt; NX_Q6UXX9; -.
DR   OpenTargets; ENSG00000147655; -.
DR   Orphanet; 3301; Tetraamelia-multiple malformations syndrome.
DR   PharmGKB; PA142670968; -.
DR   VEuPathDB; HostDB:ENSG00000147655.10; -.
DR   eggNOG; KOG3525; Eukaryota.
DR   GeneTree; ENSGT00940000159194; -.
DR   HOGENOM; CLU_064219_1_0_1; -.
DR   InParanoid; Q6UXX9; -.
DR   OMA; KQHSIFL; -.
DR   OrthoDB; 1441603at2759; -.
DR   PhylomeDB; Q6UXX9; -.
DR   TreeFam; TF331799; -.
DR   PathwayCommons; Q6UXX9; -.
DR   Reactome; R-HSA-4641263; Regulation of FZD by ubiquitination.
DR   SIGNOR; Q6UXX9; -.
DR   BioGRID-ORCS; 340419; 4 hits in 985 CRISPR screens.
DR   ChiTaRS; RSPO2; human.
DR   GeneWiki; RSPO2; -.
DR   GenomeRNAi; 340419; -.
DR   Pharos; Q6UXX9; Tbio.
DR   PRO; PR:Q6UXX9; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   RNAct; Q6UXX9; protein.
DR   Bgee; ENSG00000147655; Expressed in lung and 124 other tissues.
DR   ExpressionAtlas; Q6UXX9; baseline and differential.
DR   Genevisible; Q6UXX9; HS.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0008201; F:heparin binding; IEA:UniProtKB-KW.
DR   GO; GO:0005102; F:signaling receptor binding; IPI:UniProtKB.
DR   GO; GO:0030282; P:bone mineralization; IEA:Ensembl.
DR   GO; GO:0071542; P:dopaminergic neuron differentiation; IEA:Ensembl.
DR   GO; GO:0035115; P:embryonic forelimb morphogenesis; IEA:Ensembl.
DR   GO; GO:0035116; P:embryonic hindlimb morphogenesis; IEA:Ensembl.
DR   GO; GO:0060441; P:epithelial tube branching involved in lung morphogenesis; IEA:Ensembl.
DR   GO; GO:0060173; P:limb development; IMP:UniProtKB.
DR   GO; GO:0060437; P:lung growth; IEA:Ensembl.
DR   GO; GO:0042489; P:negative regulation of odontogenesis of dentin-containing tooth; IEA:Ensembl.
DR   GO; GO:0001649; P:osteoblast differentiation; IEA:Ensembl.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:0030177; P:positive regulation of Wnt signaling pathway; IDA:UniProtKB.
DR   GO; GO:0060535; P:trachea cartilage morphogenesis; IEA:Ensembl.
DR   GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW.
DR   CDD; cd00064; FU; 1.
DR   Gene3D; 2.20.100.10; -; 1.
DR   InterPro; IPR006212; Furin_repeat.
DR   InterPro; IPR009030; Growth_fac_rcpt_cys_sf.
DR   InterPro; IPR042993; RSPO2/4.
DR   InterPro; IPR043601; Rspo_Fu-CRD_dom.
DR   InterPro; IPR000884; TSP1_rpt.
DR   InterPro; IPR036383; TSP1_rpt_sf.
DR   PANTHER; PTHR46987:SF4; PTHR46987:SF4; 1.
DR   Pfam; PF15913; Furin-like_2; 1.
DR   SMART; SM00261; FU; 2.
DR   SMART; SM00209; TSP1; 1.
DR   SUPFAM; SSF57184; SSF57184; 1.
DR   SUPFAM; SSF82895; SSF82895; 1.
DR   PROSITE; PS50092; TSP1; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Developmental protein; Disease variant;
KW   Disulfide bond; Glycoprotein; Heparin-binding; Reference proteome;
KW   Secreted; Sensory transduction; Signal; Wnt signaling pathway.
FT   SIGNAL          1..21
FT                   /evidence="ECO:0000255"
FT   CHAIN           22..243
FT                   /note="R-spondin-2"
FT                   /id="PRO_0000234439"
FT   REPEAT          90..134
FT                   /note="FU"
FT   DOMAIN          144..204
FT                   /note="TSP type-1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   CARBOHYD        160
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        40..46
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DISULFID        43..52
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DISULFID        55..74
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DISULFID        78..93
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DISULFID        96..104
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DISULFID        101..110
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DISULFID        113..124
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DISULFID        128..141
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DISULFID        145..187
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DISULFID        156..163
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DISULFID        196..203
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   VAR_SEQ         1..67
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_018321"
FT   VAR_SEQ         32..95
FT                   /note="ASYVSNPICKGCLSCSKDNGCSRCQQKLFFFLRREGMRQYGECLHSCPSGYY
FT                   GHRAPDMNRCAR -> G (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_018322"
FT   VAR_SEQ         143
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_018323"
FT   VARIANT         69
FT                   /note="R -> C (in HHRRD; loss of LGR5-, RNF43- and ZNRF3-
FT                   binding; decreased ability to amplify WNT3A signaling;
FT                   dbSNP:rs758888137)"
FT                   /evidence="ECO:0000269|PubMed:29769720"
FT                   /id="VAR_081036"
FT   VARIANT         70..243
FT                   /note="Missing (in TETAMS2; loss of LGR5-, RNF43- and
FT                   ZNRF3-binding; complete loss of amplification of WNT3A
FT                   signaling)"
FT                   /evidence="ECO:0000269|PubMed:29769720"
FT                   /id="VAR_081037"
FT   VARIANT         137..243
FT                   /note="Missing (in TETAMS2)"
FT                   /evidence="ECO:0000269|PubMed:29769720"
FT                   /id="VAR_081038"
FT   VARIANT         186
FT                   /note="L -> P (in dbSNP:rs601558)"
FT                   /evidence="ECO:0000269|PubMed:12975309,
FT                   ECO:0000269|PubMed:14702039, ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|Ref.4"
FT                   /id="VAR_026247"
FT   MUTAGEN         105
FT                   /note="F->A: Loss of LGR5-binding, no effect on interaction
FT                   with RNF43 and ZNRF3, no effect on WNT3A signaling; when
FT                   associated with A-109."
FT                   /evidence="ECO:0000269|PubMed:29769720"
FT   MUTAGEN         109
FT                   /note="F->A: Loss of LGR5-binding, no effect on interaction
FT                   with RNF43 and ZNRF3, no effect on WNT3A signaling; when
FT                   associated with A-105."
FT                   /evidence="ECO:0000269|PubMed:29769720"
SQ   SEQUENCE   243 AA;  28315 MW;  96F44F105B21BB52 CRC64;
     MQFRLFSFAL IILNCMDYSH CQGNRWRRSK RASYVSNPIC KGCLSCSKDN GCSRCQQKLF
     FFLRREGMRQ YGECLHSCPS GYYGHRAPDM NRCARCRIEN CDSCFSKDFC TKCKVGFYLH
     RGRCFDECPD GFAPLEETME CVEGCEVGHW SEWGTCSRNN RTCGFKWGLE TRTRQIVKKP
     VKDTILCPTI AESRRCKMTM RHCPGGKRTP KAKEKRNKKK KRKLIERAQE QHSVFLATDR
     ANQ
//
